GCP
URGN icon

GSA Capital Partners’s UroGen Pharma URGN Stock Holding History

GSA Capital Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,964
Closed -$977K – 2107
2025
Q3 		$977K Buy
+48,964
New +$879K 0.08% 417
2024
Q4 		– Sell
-19,597
Closed -$249K – 2050
2024
Q3 		$249K Buy
+19,597
New +$291K 0.02% 1320
2024
Q2 		– Sell
-14,937
Closed -$224K – 2043
2024
Q1 		$224K Buy
+14,937
New +$244K 0.02% 1358
2023
Q4 		– Sell
-10,189
Closed -$143K – 1956
2023
Q3 		$143K Buy
+10,189
New +$164K 0.01% 1349
2023
Q1 		– Sell
-31,046
Closed -$275K – 1953
2022
Q4 		$275K Sell
31,046
-18,176
-37% -$172K 0.03% 993
2022
Q3 		$410K Buy
49,222
+951
+2% +$7.87K 0.05% 723
2022
Q2 		$395K Sell
48,271
-8,953
-16% -$61.5K 0.06% 650
2022
Q1 		$498K Buy
57,224
+18,160
+46% +$142K 0.07% 536
2021
Q4 		$371K Buy
39,064
+18,559
+91% +$262K 0.05% 794
2021
Q3 		$345K Sell
20,505
-7,378
-26% -$117K 0.04% 921
2021
Q2 		$426K Buy
27,883
+4,339
+18% +$78.5K 0.05% 734
2021
Q1 		$459K Buy
+23,544
New +$500K 0.08% 401
2018
Q1 		– Sell
-10,200
Closed -$380K – 1840
2017
Q4 		$380K Buy
10,200
+900
+10% +$32K 0.02% 1090
2017
Q3 		$293K Buy
+9,300
New +$205K 0.02% 1265

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

GSA Capital Partners's URGN Position: Q4 2025 in Review

GSA Capital Partners sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 48,964 shares — an estimated $977K sold.

GSA Capital Partners first reported a position in URGN in Q3 2017 and held it in 14 quarters. The position peaked at $977K in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • GSA Capital Partners reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 48,964 UroGen Pharma shares in Q4 2025, an estimated $977K.
  • GSA Capital Partners first reported a position in UroGen Pharma in Q3 2017 and held it in 14 quarters.
  • GSA Capital Partners's UroGen Pharma position peaked at $977K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.